Navigation Links
AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.

SOURCE AETERNA ZENTARIS INC.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Announces Appointment of New Board Member
2. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
5. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
6. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
7. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
8. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
9. AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
10. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Dendreon Corporation (Nasdaq: DNDN ) today announced that management ... Healthcare Conference in New York City, NY on May 25, 2011 ... in Rancho Palos Verdes, CA on June 7, 2011 at 2:00 ... live and available for replay from Dendreon,s website, www.dendreon.com . ...
... BRISBANE, Calif., May 19, 2011 InterMune, Inc. (NASDAQ: ... of its 2011 Analyst Day presentations on Thursday, May ... in New York.  Presentations by InterMune,s executive management team ... and a comprehensive update of InterMune,s commercial and scientific ...
... CARY, N.C., May 19, 2011 ... its flexible 100% web-based Life Science Study Management ... successfully used globally by Leading European and USA ... eStudy,s on-line study design, management, communication, data collection ...
Cached Biology Technology:InterMune to Webcast 2011 Analyst Day Presentations 2Leading Ag Biotechnology Companies in Europe and America Save 50-80% of Field Study Management Time with eStudy 2Leading Ag Biotechnology Companies in Europe and America Save 50-80% of Field Study Management Time with eStudy 3
(Date:7/9/2014)... geographic ranges in which animals can be found, concern ... Does an increased range for a host mean new ... says a team of UC Santa Barbara scientists, including ... published in the Journal of Biogeography , Hechinger, ... opposite may happen: Hosts may actually lose their parasites ...
(Date:7/9/2014)... (July 9, 2014) Emerging fungal pathogens pose ... parasitic group, causing population declines of amphibians, bats, ... University of South Florida published in the prestigious ... acquire behavioral or immunological resistance to a deadly ... , "Acquired resistance is important because it ...
(Date:7/9/2014)... injuries have identified an immune marker that predicts ... infection. The study, led by clinician-scientists at Nationwide ... the journal Shock , is part of ... clinical implementation of quick-turnaround immune function tests and ... following critical illness or injury in pediatric patients. ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4USF study: Amphibians can acquire resistance to deadly fungus 2Immune function predicts infection risk among child trauma patients 2Immune function predicts infection risk among child trauma patients 3
... stem cells, ability to regenerate damaged tissue could offer ... myopathy and muscular dystrophy, according to researchers from the ... procedure has been successfully used to regrow muscles in ... all tissue-based illnesses in humans such as in the ...
... young, apparently healthy athletes suddenly collapse, it can be due ... have now discovered a genetic modification that leads to cardiac ... can give zebrafish a heart condition. Since the fish have ... could be critical for humans as well. ...
... and Innovation in Global BiometricsGAITHERSBURG, Md., March 4 ... has been named the Biometrics Systems Integrator "Company ... the Corporation,s leadership in developing innovative biometrics solutions ... Sullivan based the award on a rigorous analysis ...
Cached Biology News:Stem cell breakthrough gives new hope to sufferers of muscle-wasting diseases 2Why 'lazy Susan' has a weak heart 2Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2
...
... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
...
Request Info...
Biology Products: